Grégory Behar
Chief Executive Officer bei RECIPHARM AB (PUBL)
Vermögen: 4 Mio $ am 31.03.2024
Profil
Grégory Behar is currently the Chief Executive Officer at Recipharm AB and the President & CEO at Nestle Health Science SA (Private Equity).
He is also the Chairman of Nutrition Science Partners Ltd.
and serves as an Independent Non-Executive Director at Sonova Holding AG.
Additionally, he holds positions as a Director at Prometheus Laboratories, Inc., Amazentis SA, and Nestlé Health Science (Deutschland) GmbH.
In his former roles, Mr. Behar served as the President & Chief Executive Officer at Boehringer Ingelheim Pharmaceuticals, Inc. from 2011 to 2014.
He was also the Chief Executive Officer at Nestle Health Science SA and Nestlé Health Science France SAS.
Furthermore, he held the position of Director at Cerecin, Inc. and served as an Independent Director at Seres Therapeutics, Inc. from 2014 to 2023.
He was an Independent Director at Axcella Health, Inc. from 2016 to 2022 and at Aimmune Therapeutics, Inc. from 2016 to 2020.
Mr. Behar also held the position of Vice President-NECAR Region at Boehringer Ingelheim GmbH from 2010 to 2011 and worked as a Manager at Nestlé SA from 1995 to 2000.
Mr. Behar completed his graduate studies at École Polytechnique Fédérale de Lausanne and his undergraduate studies at the University of California, Los Angeles.
He also holds an MBA from INSEAD.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NESTLE S.A.
0,00% | 31.12.2023 | 35 692 ( 0,00% ) | 4 Mio $ | 31.03.2024 |
SERES THERAPEUTICS INC
-.--% | 22.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Grégory Behar
| Unternehmen | Position | Beginn |
|---|---|---|
| SONOVA HOLDING AG | Director/Board Member | 15.06.2021 |
| RECIPHARM AB (PUBL) | Chief Executive Officer | 01.01.2024 |
Amazentis SA
 Amazentis SA Miscellaneous Commercial ServicesCommercial Services Amazentis SA is a Swiss innovative life science company that focuses on developing products targeting mitochondrial health for advanced nutrition. The company was founded in 2007 by Pierre Landolt, Patrick Aebischer, and Chris Rinsch, and it is currently based in Lausanne, Switzerland. The company has published its research on Mitopure™ Urolithin A in top peer-reviewed scientific journals, including Nature Medicine, Nature Metabolism, JAMA Network Open, and European Journal of Clinical Nutrition. Amazentis has a strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™. Brian Ray has been the CEO of the company since 2023. | Director/Board Member | - |
Prometheus Laboratories, Inc.
 Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Director/Board Member | - |
Nestlé Health Science (Deutschland) GmbH
 Nestlé Health Science (Deutschland) GmbH Pharmaceuticals: OtherHealth Technology Nestlé Health Science (Deutschland) GmbH is a private company based in Frankfurt, Germany. Part of Nestlé SA, the German company develops nutritional therapies. The company was founded in 2011 and the CEO is Arne Ingo Jurk. | Director/Board Member | - |
Nestle Health Science SA (Private Equity)
 Nestle Health Science SA (Private Equity) Investment ManagersFinance Nestle Health Science SA (Private Equity) is a private equity firm headquarter in Switzerland. It was founded in 2010 by Jason Brown and Persona. | Chief Executive Officer | 01.07.2014 |
Nutrition Science Partners Ltd.
 Nutrition Science Partners Ltd. Miscellaneous Commercial ServicesCommercial Services Nutrition Science Partners Ltd. principally engages in the research and development of pharmaceutical products. The company was founded on May 28, 2012 and is headquartered in Hong Kong. | Chairman | - |
Ehemalige bekannte Positionen von Grégory Behar
| Unternehmen | Position | Ende |
|---|---|---|
| SERES THERAPEUTICS, INC. | Director/Board Member | 02.10.2023 |
| AXCA HEALPAR | Director/Board Member | 19.05.2022 |
| ░░░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░ ░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Grégory Behar
| École Polytechnique Fédérale de Lausanne | Graduate Degree |
| University of California, Los Angeles | Undergraduate Degree |
| INSEAD | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 4 |
|---|---|
| NESTLÉ S.A. | Consumer Non-Durables |
| SONOVA HOLDING AG | Health Technology |
| SERES THERAPEUTICS, INC. | Health Technology |
| AXCA HEALPAR | Health Technology |
| Private Unternehmen | 13 |
|---|---|
Boehringer Ingelheim GmbH
 Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
Cerecin, Inc.
 Cerecin, Inc. Pharmaceuticals: MajorHealth Technology Cerecin, Inc. develops therapies to treat central nervous system disorders. It offers therapeutic treatments for Parkinson's disease, Alzheimer's disease, and other age-related memory loss disorders. The firm is also developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells. The company was founded in 2001 and is headquartered in Boulder, CO. | Health Technology |
Recipharm AB
 Recipharm AB BiotechnologyHealth Technology Recipharm AB engages in the manufacture of pharmaceuticals and contract development services for pharmaceutical companies. It operates through the following segments: Manufacturing Sterile and Inhalation (MFG-SI); Manufacturing Solids and Others (MFG-SO); Development and Technology (D&T); and Others and Eliminations. The MFG-SI segment includes manufacturing of products on behalf of pharmaceutical companies and covers sterile and inhalation technologies as well as liquid vials and ampoules, lyophilisates, blow-fill-seal products, and inhalation. The MFG-SO segment produces products on behalf of pharmaceutical companies and covers tablets, capsules, semi-solids, and non-sterile liquids. The D&T segment focuses on pharmaceutical development services. The company was founded by Lars Rickard Backsell and Thomas Bengt Eldered in 1995 and is headquartered in Stockholm, Sweden. | Health Technology |
Prometheus Laboratories, Inc.
Prometheus Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Prometheus Laboratories, Inc. develops and commercializes novel pharmaceutical and diagnostic products. Its enables physicians to provide individualized patient care. It applies the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and applies it to oncology. The firms markets and promotes pharmaceutical products and complementary proprietary diagnostic testing services. The company was founded by Jonathan Braun, Stephan R. Targan, Michael J. Walsh, and Scott L. Glenn in 1995 and is headquartered in San Diego, CA. | Health Technology |
Boehringer Ingelheim Pharmaceuticals, Inc.
 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT. | Health Technology |
Amazentis SA
Amazentis SA Miscellaneous Commercial ServicesCommercial Services Amazentis SA is a Swiss innovative life science company that focuses on developing products targeting mitochondrial health for advanced nutrition. The company was founded in 2007 by Pierre Landolt, Patrick Aebischer, and Chris Rinsch, and it is currently based in Lausanne, Switzerland. The company has published its research on Mitopure™ Urolithin A in top peer-reviewed scientific journals, including Nature Medicine, Nature Metabolism, JAMA Network Open, and European Journal of Clinical Nutrition. Amazentis has a strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™. Brian Ray has been the CEO of the company since 2023. | Commercial Services |
Nestle Health Science SA
 Nestle Health Science SA Pharmaceuticals: OtherHealth Technology Nestle Health Science SA develops nutritional therapies. Its health management services include aging, brain health, chronic medical conditions, critical care and surgery, food allergy, gastro intestinal, metabolic diseases, and obesity pediatrics. The company was founded in 2011 and is headquartered in Vevey, Switzerland. | Health Technology |
Nestle Health Science SA (Private Equity)
Nestle Health Science SA (Private Equity) Investment ManagersFinance Nestle Health Science SA (Private Equity) is a private equity firm headquarter in Switzerland. It was founded in 2010 by Jason Brown and Persona. | Finance |
Aimmune Therapeutics, Inc.
 Aimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The firm product include Palforzia, which is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis that may occur with accidental exposure to peanut. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. | Health Technology |
Prometheus Biosciences, Inc.
 Prometheus Biosciences, Inc. BiotechnologyHealth Technology Prometheus Biosciences, Inc. engages in operation of a biopharmaceutical company. It focuses on the discovery, development, and commercialization of novel precision therapeutics and companion diagnostics for patients living with unmet needs in gastroenterology and autoimmune diseases. The company was founded by Scott Glenn and Stephan Targan on October 26, 2016 and is headquartered in San Diego, CA . | Health Technology |
Nutrition Science Partners Ltd.
Nutrition Science Partners Ltd. Miscellaneous Commercial ServicesCommercial Services Nutrition Science Partners Ltd. principally engages in the research and development of pharmaceutical products. The company was founded on May 28, 2012 and is headquartered in Hong Kong. | Commercial Services |
Nestlé Health Science (Deutschland) GmbH
Nestlé Health Science (Deutschland) GmbH Pharmaceuticals: OtherHealth Technology Nestlé Health Science (Deutschland) GmbH is a private company based in Frankfurt, Germany. Part of Nestlé SA, the German company develops nutritional therapies. The company was founded in 2011 and the CEO is Arne Ingo Jurk. | Health Technology |
Nestlé Health Science France SAS
 Nestlé Health Science France SAS Pharmaceuticals: OtherHealth Technology Nestlé Health Science France SAS is a private company based in Issy-les-Moulineaux, France. Part of Nestlé SA, Nestlé Health Science France SAS manufactures and distributes nutritional health care products. The CEO of the French company is Grégory Behar. | Health Technology |
